Facebook Linkedin Mail X Youtube
Facebook Linkedin Mail X Youtube

Tag: PB2452

PhaseBio receives FDA breakthrough therapy designation for PB2452 for the reversal of the antiplatelet activity of ticagrelor

PhaseBio Pharmaceuticals,...
Cardiovascular News

Write to us
Editorial: Will Date will@bibamedical.com
Advertising: Hannah Shiels hannah@bibamedical.com


BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: info@bibamedical.com

Terms and Conditions | Privacy Policy
Facebook Linkedin Mail X Youtube